Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451250 | 0.90 | ALDH1A1 (0.76) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15154187 | 0.89 | MEN1 (0.64) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4957798 | 0.87 | MEN1 (0.86) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4393425 | 0.85 | ALDH1A1 (0.76) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL453594 | 0.83 | ALDH1A1 (0.76) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL410839 | 0.83 | PDE10A (1.00) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15154005 | 0.83 | PDE10A (0.77) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL409489 | 0.81 | PDE10A (1.00) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29175100 | 0.81 | ALDH1A1 (0.70) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL411000 | 0.80 | PDE10A (1.00) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435048-B1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2435048-B1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-07-03 | — | — | EP | disclosed |
| US-8846000-B2 | Radiolabeled PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846000-B2 | Radiolabeled PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846000-B2 | Radiolabeled PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| WO-2012058133-A1 | ISOINDOLINONE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| WO-2010138585-A1 | PYRIMIDINONES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138577-A1 | RADIOLABELED PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064005-A1 | RADIOLABELED PDE10 INHIBITORS | PDE5A, PDE3A, PDE10A | MEN1 791/4885CYP1A2 967/4885CYP3A4 2451/4885 |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | PDE12, PDE10A, PDE4A | MEN1 4425/4885CYP1A2 989/4885CYP3A4 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.